Vascular endothelial growth factor

Polymorphisms of vascular endothelial growth factor on prognosis in hepatocellular carcinoma patients receiving transcatheter arterial chemoembolization treatment

J. Song, Wang, L. Z., Li, X., Jiang, T. P., An, T. Z., Xu, M., Wu, X. P., and Zhou, S., Polymorphisms of vascular endothelial growth factor on prognosis in hepatocellular carcinoma patients receiving transcatheter arterial chemoembolization treatment, vol. 13, pp. 8946-8953, 2014.

We conducted a cohort study to investigate the prognostic significance of vascular endothelial growth factor (VEGF) polymorphisms in hepatocellular carcinoma (HCC) patients after transcatheter arterial chemoembolization (TACE). In total, 156 patients with histologically confirmed HCC within 2 months were collected from January 2007 to January 2008. The genotypes of VEGF-2578C/A, -1154G/A, -634C/G, and -1498T/C were determined from blood extracted using a blood kit on a 384-well plate. The survival rate at 5 years was 55.47%.

Subscribe to Vascular endothelial growth factor